Differential effects of acute and chronic haloperidol treatment on striatal and nigral 3,4-dihydroxyphenylacetic acid (DOPAC) levels.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006220:Haloperidol / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects* / Q000378:metabolism
D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D006220:Haloperidol